| Prev Close | 192.99 |
| Open | 193.01 |
| Day Low/High | 191.64 / 193.38 |
| 52 Wk Low/High | 114.27 / 202.22 |
| Volume | 12.44M |
Allergan plc (AGN)
193.02
0.03
0.02
NYSE
| Exchange | NYSE |
| Div & Yield | N.A. (N.A) |
Quick News on Goldman, Allergan
Brother Bank of America/Mother Merrill makes Goldman Sachs a US 1 List addition this morning. The shares are up slightly in early trading. Also, Argus lowers its Allergan rating this morning.
Some Afternoon Observations
* Thus far, my expectation of an "inside day" has been accurate. SPDR S&P 500 ETF has traded in a fifty cent range most of the day. * Bonds are at the day's highs. +$0.88. Yield on the 10-year U.S. note is down by 3.5 basis points to 2.32% (where y...
My Former Love Allergan Still Looks Unattractive
"When the facts change, I change my mind. What do you do, sir?" - John Maynard Keynes I started 2017 with the expectation that Allergan would be among the best-performing large-cap stocks extant. For a while the shares performed well relative to ex...
Allergan, BioMarin Hold Promise for 2018
The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.
How to Protect Yourself From the Vicious Market Rotation
If we continue to see volatility, then I'll consider some out-of-the-money put sales.
Protect Yourself From the Rotation
If we continue to see volatility, then I'll consider some out-of-the-money put sales.
Video: Jim Cramer's Outlook on Allergan and Illinois Tool Works
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer thinks Allergan is a buy at current levels and reacts to the recent analyst price target raises tied to Illinois Tool Works.
Mid-Afternoon Observations
Some mid afternoon observations: * Small yield flattening in today's session and little change in bond yields. * High yield is slipping a bit. * The U.S. Dollar is strengthening after morning weakness. * Oil down after weeks of strength (-$0.76/ba...
Cramer: This Is the Era of Good Feelings
Thanksgiving week frequently sees buyers pay up and sellers walk away.
Here's What's Up This A.M.
The Nasdaq (QQQs) turn slightly negative as most of the FANGs reverse lower. Retail, generics (Teva and Mylan ), big pharma (Merck and Bristol-Myers Squibb ) and biotech (Allergan , Gilead Sciences , Celgene ) are conspicuous to the downside. Co...
Big-Cap Biotechs Are Dragging
Biotech is conspicuously weak, with weakness in Allergan , Celgene and Gilead Sciences . I suspect we could see tax selling in December, but it's still early. Speculative biotech is not much better. I am avoiding the sector for now.
Action Alerts PLUS: Bulls Cheer Apple Results, Fed Chairman Nominee
A heavy load of economic data and earnings, led by Apple, dominated the week's business news.
Allergan's Drop Provides 10 Important Investing Lessons
On Thursday, I waved the white flag exited my AGN position.
Cramer: Is There Less of a Fear Factor About Stocks?
There's anecdotal evidence, but I'm still getting a lot fewer questions about them.
Allergan's Ten Important Lessons
To me, there are a number of important lessons in Allergan's $11 drop today: There is no substitute for objective and hard-hitting security analysis. A variant view can be special and deliver alpha -- it can contribute importantly to avoiding los...
Video: Jim Cramer on Facebook, Alibaba, Allergan, Newell Brands and Kraft Heinz
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer analyzes Thursday's trending stocks.
Potholes in the Market
Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City. Today's potholes: * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...
This Allergan Bull Reluctantly Waves the White Flag and Exits the Stock
Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.
How Short Should I Get?
With my additional shorts in the last few days, I have substantially raised the size and my cost basis in Amazon . The same applies to Facebook . To me, my decision, based on an assessment of upside/downside in the market and in individual shorts,...
How Short Should I Get?
With my additional shorts in the last few days, I have substantially raised the size and my cost basis in Amazon . The same applies to Facebook . To me, my decision, based on an assessment of upside/downside in the market and in individual shorts,...
Trimming More Allergan
I have moved back to medium sized in Allergan -- having sold off a bit more at $186.20.
Video: Jim Cramer on Allergan, Estee Lauder, Electronic Arts, Clorox and Apple
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
Trimming Allergan
Took small Allergan off at $184 just for kicks and discipline -- more than $10 above today's cost basis. Gives me some leeway to add on any weakness.
U.S. Steel Powers Materials Rally
Shares of United States Steel surged after posting a solid quarter.
Allergan Surging
Allergan ripping now (+$7 on the day and +$15 from the day's lows) on some favorable analyst comments.
Jim Cramer on Allergan: I Wanted a Breakup
While TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer said Allergan's results were "fine" but he wanted a breakup of the company.
Here's a Scorecard Update
I added to Allergan long at $173.45 -- went "grande." I added to a sizable SPDR S&P 500 short at $258.25. I covered my small Electronic Arts short rental at $113.
Big on Allergan and Bregman
Allergan has more moves than Houston Astros third baseman Alex Bregman.
I'm Big Into Allergan
I have moved to a large Allergan position with today's purchases at an average of $173.42.